Scott D. Lunin

1.3k total citations
21 papers, 297 citations indexed

About

Scott D. Lunin is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Scott D. Lunin has authored 21 papers receiving a total of 297 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pathology and Forensic Medicine, 9 papers in Genetics and 6 papers in Oncology. Recurrent topics in Scott D. Lunin's work include Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (8 papers) and Acute Myeloid Leukemia Research (5 papers). Scott D. Lunin is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (8 papers) and Acute Myeloid Leukemia Research (5 papers). Scott D. Lunin collaborates with scholars based in United States, Canada and United Kingdom. Scott D. Lunin's co-authors include Jeffrey Schlom, Sam Zaremba, Stephen F. Stanziale, Scott I. Abrams, John D. Hainsworth, F. Anthony Greco, Ian W. Flinn, David R. Spigel, Hagop M. Kantarjian and Dianna Shipley and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Scott D. Lunin

20 papers receiving 289 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Scott D. Lunin United States 9 125 102 92 88 84 21 297
Rebecca Kan United States 6 75 0.6× 193 1.9× 48 0.5× 41 0.5× 96 1.1× 7 322
Bradley Long United States 10 94 0.8× 122 1.2× 87 0.9× 99 1.1× 45 0.5× 12 380
Yuhua Feng China 13 208 1.7× 130 1.3× 53 0.6× 114 1.3× 53 0.6× 27 433
Johannes Andel Austria 10 95 0.8× 254 2.5× 28 0.3× 56 0.6× 98 1.2× 30 429
Yayan Zhang United States 7 65 0.5× 331 3.2× 37 0.4× 142 1.6× 148 1.8× 10 440
Aneta Schieferdecker Germany 7 83 0.7× 96 0.9× 29 0.3× 26 0.3× 28 0.3× 17 203
Julie C. Porcher United States 8 106 0.8× 126 1.2× 71 0.8× 213 2.4× 69 0.8× 13 399
Julianna Supplee United States 9 216 1.7× 270 2.6× 29 0.3× 121 1.4× 58 0.7× 13 708
Benedetta Urbini Italy 10 93 0.7× 121 1.2× 165 1.8× 37 0.4× 185 2.2× 23 462
JM Hernández Spain 8 187 1.5× 115 1.1× 100 1.1× 54 0.6× 51 0.6× 12 426

Countries citing papers authored by Scott D. Lunin

Since Specialization
Citations

This map shows the geographic impact of Scott D. Lunin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott D. Lunin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott D. Lunin more than expected).

Fields of papers citing papers by Scott D. Lunin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott D. Lunin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott D. Lunin. The network helps show where Scott D. Lunin may publish in the future.

Co-authorship network of co-authors of Scott D. Lunin

This figure shows the co-authorship network connecting the top 25 collaborators of Scott D. Lunin. A scholar is included among the top collaborators of Scott D. Lunin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott D. Lunin. Scott D. Lunin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sharman, Jeff P., Danielle M. Brander, Anthony R. Mato, et al.. (2021). Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. The Lancet Haematology. 8(4). e254–e266. 39 indexed citations
2.
Sharman, Jeff P., Danielle M. Brander, Anthony R. Mato, et al.. (2020). Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study.. Journal of Clinical Oncology. 38(15_suppl). 8022–8022. 7 indexed citations
3.
4.
Weaver, David T., Kam Sprott, Jonathan A. Pachter, et al.. (2018). Duvelisib inhibition of chemokines in patients with CLL (DUO study) and iNHL (DYNAMO study).. Journal of Clinical Oncology. 36(15_suppl). 12048–12048. 2 indexed citations
5.
Roboz, Gail J., Hagop M. Kantarjian, Karen Yee, et al.. (2017). Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 124(2). 325–334. 49 indexed citations
6.
Zinzani, Pier Luigi, Nina D. Wagner‐Johnston, Carole B. Miller, et al.. (2017). DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE‐REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA. Hematological Oncology. 35(S2). 69–70. 11 indexed citations
7.
Sharman, Jeff P., Danielle M. Brander, Anthony R. Mato, et al.. (2017). Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study.. Journal of Clinical Oncology. 35(15_suppl). 7504–7504. 7 indexed citations
8.
Donnellan, William B., Jesús G. Berdeja, Edward Arrowsmith, et al.. (2017). A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia. The Oncologist. 22(10). 1156–e111. 2 indexed citations
9.
Sharman, Jeffrey P., Danielle M. Brander, Anthony R. Mato, et al.. (2017). UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY. Hematological Oncology. 35(S2). 111–112. 4 indexed citations
10.
Flinn, Ian W., Carole B. Miller, Kirit M. Ardeshna, et al.. (2016). Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma. Blood. 128(22). 1218–1218. 18 indexed citations
11.
Hainsworth, John D., F. Anthony Greco, Eric Raefsky, et al.. (2014). Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 14(4). 277–283. 18 indexed citations
12.
13.
Griffiths, Elizabeth A., Hagop M. Kantarjian, Gail J. Roboz, et al.. (2014). First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML).. Journal of Clinical Oncology. 32(15_suppl). 7030–7030. 5 indexed citations
14.
Hainsworth, John D., David R. Spigel, Howard A. Burris, et al.. (2009). Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer. 115(10). 2138–2146. 30 indexed citations
15.
Lunin, Scott D., David R. Spigel, John D. Hainsworth, et al.. (2008). Phase II trial of vinflunine (VFL) in sensitive and refractory relapsed small-cell lung cancer (SCLC): Updated results. Journal of Clinical Oncology. 26(15_suppl). 19028–19028. 2 indexed citations
16.
Peyton, James D., David R. Spigel, John D. Hainsworth, et al.. (2007). Phase II trial of vinflunine in patients with relapsed small cell lung cancer. Journal of Clinical Oncology. 25(18_suppl). 18091–18091. 7 indexed citations
17.
18.
Verstovšek, Srđan, Scott D. Lunin, Hagop M. Kantarjian, et al.. (2003). Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leukemia Research. 27(7). 661–669. 28 indexed citations
19.
Lunin, Scott D. & Stephan Moll. (2001). Suppurative Parotitis. New England Journal of Medicine. 345(9). 662–662. 1 indexed citations
20.
Abrams, Scott I., Stephen F. Stanziale, Scott D. Lunin, Sam Zaremba, & Jeffrey Schlom. (1996). Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses. European Journal of Immunology. 26(2). 435–443. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rebecca Kan Breakdown of academic impact, for papers by Bradley Long Breakdown of academic impact, for papers by Yuhua Feng Breakdown of academic impact, for papers by Johannes Andel Breakdown of academic impact, for papers by Yayan Zhang Breakdown of academic impact, for papers by Aneta Schieferdecker Breakdown of academic impact, for papers by Julie C. Porcher Breakdown of academic impact, for papers by Julianna Supplee Breakdown of academic impact, for papers by Benedetta Urbini Breakdown of academic impact, for papers by JM Hernández
Rankless by CCL
2026